Overview

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Status:
Terminated
Trial end date:
2020-02-25
Target enrollment:
Participant gender:
Summary
This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
Phase:
Phase 1
Details
Lead Sponsor:
Basilea Pharmaceutica
Treatments:
Anti-Bacterial Agents
Ceftobiprole
Ceftobiprole medocaril
Cephalosporins